Historique
Article de Périodique
Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin (2007)
(Expérience randomisée sur la densité du renforcement basé sur le gain dans le cas d'une abstinence simultanée à l'héroïne et la cocaïne)
Auteur(s) :
GHITZA, U. E. ;
EPSTEIN, D. H. ;
SCHMITTNER, J. ;
VAHABZADEH M. ;
LIN, J. L. ;
PRESTON, K. L.
Année
2007
Page(s) :
765-774
Langue(s) :
Anglais
Refs biblio. :
42
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
COCAINE
;
HEROINE
;
ABSTINENCE
;
METHADONE
;
ENQUETE
;
METHODE
;
COMPARAISON
;
EVALUATION
Note générale :
Journal of Consulting and Clinical Psychology, 2007, 75, (5), 765-774
Note de contenu :
fig. ; tabl.
Résumé :
ENGLISH :
To examine the effect of reinforcer density in prize-based abstinence reinforcement, heroin/cocaine users (N = 116) in methadone maintenance (100 mg/day) were randomly assigned to a noncontingent control group (NonC) or to 1 of 3 groups that earned prize draws for abstinence: manual drawing with standard prize density (MS) or computerized drawing with standard (CS) or high (CH) density. Probabilities (prizes/draw) were standard (50%) and high (78%); prize density was double blind. Mean prize values were CH, CS, MS, and NonC, $171. Outcomes were % opioid/cocaine-negative urines during the 12-week intervention and then 8 weeks postintervention as well as diagnosis of dependence up to 6 months poststudy. CH had significantly more negative specimens than did NonC during intervention and had more than all groups during postintervention treatment: Mean % negative (95% confidence interval) during postintervention treatment adjusted for baseline drug use and dropout were CH, 55% (14%-90%); CS, 7% (1%-27%); MS, 4% (1%-12%); and NonC, 3% (1%-10%). Current cocaine dependence diagnoses after treatment were significantly lower in contingent compared with noncontingent groups. Computerized drawing with higher-density prizes enhanced reduction of cocaine use; abstinence reinforcement had long-term therapeutic benefits (Author' s abstract)
Affiliation :
Etats-Unis. United States.
Cote :
Abonnement